Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BVXV BiondVax制药
2.650+0.060+2.32%
Close
02/03 16:00 ET
2.640-0.010-0.38%
Post Mkt Price 02/03 19:19 ET
High
2.677
Open
2.570
Turnover
230.58K
Low
2.510
Pre Close
2.590
Volume
88.57K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
BiondVax Pharmaceuticals (NASDAQ:BVXV) Versus Bio-Techne (NASDAQ:TECH) Head-To-Head Contrast
Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Short Interest Up 206.6% in January
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 55,800 shares, a
StockNews.com Begins Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)
StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the st
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com
Equities researchers at StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage se
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
BiondVax Pharmaceuticals Ltd (NYSE:BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study compared weight loss in two grou
BiondVax Pharma Sees Positive Trial Results for NanoAb Covid-19 Drug
By Chris Wack BiondVax Pharmaceuticals Ltd. said Monday it saw positive results in a preclinical proof-of-concept study of its inhaled NanoAb Covid-19 drug. Using an industry-standard animal model,
BiondVax's Inhaled NanoAb for COVID-19 Shows Efficacy in Preclinical Study
Press Release: BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study -- COVID-19 illness was virtually prevented in ham
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Gainers Tricida, Inc. (NASDAQ:TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.Huadi International Group Co., Ltd. (NASDAQ:HUDI) rose 26.7% to $7.16 in pre-market tradi
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by StockNews.com
Research analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set
Company Overview
More
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
CEO： Mr. Amir Reichman
Market： NASDAQ
Listing Date： 05/12/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet